MétaCan
Menu
Back to cohort
Record W2524386165 · doi:10.1186/s13104-016-2256-3

Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts

2016· article· en· W2524386165 on OpenAlexaff
Stefan Vallo, Martin Michaelis, Kilian M. Gust, Peter C. Black, Florian Rothweiler, Hans Michael Kvasnicka, Roman A. Blaheta, Maximilian Peter Brandt, Felix Wezel, Axel Haferkamp, Jindřich Činátl

Bibliographic record

VenueBMC Research Notes · 2016
Typearticle
Languageen
FieldMedicine
TopicBladder and Urothelial Cancer Treatments
Canadian institutionsUniversity of British Columbia
FundersHilfe für krebskranke Kinder FrankfurtFrankfurter Stiftung für krebskranke Kinder
KeywordsDasatinibGemcitabineMedicineBladder cancerOncologyCancer researchInternal medicineCabozantinibCancerTyrosine kinaseReceptor

Abstract

fetched live from OpenAlex

Systemic chemotherapy with gemcitabine and cisplatin is standard of care for patients with metastatic urothelial bladder cancer. However, resistance formation is common after initial response. The protein Src is known as a proto-oncogene, which is overexpressed in various human cancers. Since there are controversial reports about the role of Src in bladder cancer, we evaluated the efficacy of the Src kinase inhibitor dasatinib in the urothelial bladder cancer cell line RT112 and its gemcitabine-resistant sub-line RT112 r GEMCI 20 in vitro and in vivo. RT112 urothelial cancer cells were adapted to growth in the presence of 20 ng/ml gemcitabine (RT112 r GEMCI 20 ) by continuous cultivation at increasing drug concentrations. Cell viability was determined by MTT assay, cell growth kinetics were determined by cell count, protein levels were measured by western blot, and cell migration was evaluated by scratch assays. In vivo tumor growth was tested in a murine orthotopic xenograft model using bioluminescent imaging. Dasatinib exerted similar effects on Src signaling in RT112 and RT112 r GEMCI 20 cells but RT112 r GEMCI 20 cells were less sensitive to dasatinib-induced anti-cancer effects (half maximal inhibitory concentration (IC 50 ) of dasatinib in RT112 cells: 349.2 ± 67.2 nM; IC 50 of dasatinib in RT112 r GEMCI 20 cells: 1081.1 ± 239.2 nM). Dasatinib inhibited migration of chemo-naive and gemcitabine-resistant cells. Most strikingly, dasatinib treatment reduced RT112 tumor growth and muscle invasion in orthotopic xenografts, while it was associated with increased size and muscle-invasive growth in RT112 r GEMCI 20 tumors. Dasatinib should be considered with care for the treatment of urothelial cancer, in particular for therapy-refractory cases.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.096
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.131
GPT teacher head0.421
Teacher spread0.290 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueBMC Research NotesSame topicBladder and Urothelial Cancer TreatmentsFrench-language works237,207